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Abstract 
Background: During oxaliplatin chemotherapy administration via a peripheral vein, vascular pain requires changing 
of the intravenous infusion route on occasion. Vascular pain induced by anticancer drugs reduces the rate of patient 
continuation and completion of chemotherapy. Pain is presently appraised using subjective methods, such as the 
visual analog scale (VAS). However, because pain evaluation can vary depending on the physical state and mood of 
the patient at the time of assessment, it is desirable to evaluate pain objectively. PainVision PS-2100 (PV) is a medical 
device that was designed to objectively and quantitatively assess patient nociception and perception.
Methods: The present study examined the correlation of subjective and objective assessment of oxaliplatin-induced 
vascular pain using VAS and PV, respectively.
Results: Vascular pain was assessed using both PV and VAS a total of 173 times for 58 colorectal cancer patients. 
Partial correlation analysis was performed to evaluate the relationship between PV and VAS. The mean PV and VAS 
scores were 44.5 (range: 0–596) and 24.8 (range: 0–100), respectively. The partial correlation coefficient was 0.408 
(p < 0.0001).
Conclusions: A strong correlation was not observed between the results, and a weak correlation was observed 
between VAS and PV scores. Objective evaluation of oxaliplatin-induced vascular pain will be required to help patients 
overcome vascular pain.
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Background
FOLFIRI (irinotecan with folinic acid and fluorouracil) 
and FOLFOX (oxaliplatin with folinic acid and fluoroura-
cil) therapies for colorectal cancer (CRC) require the use 
of central venous (CV) ports. Recently developed thera-
pies combining capecitabine plus oxaliplatin (XELOX) 
allow for chemotherapy via a peripheral vein without CV 
port (Yoshida et al. 2015b). However, vascular pain (VP) 
occasionally necessitates the movement of oxaliplatin 
drip infusions to a peripheral vein during XELOX ther-
apy. VP following intravenous infusion of anticancer 
drugs can be caused by osmotic pressure and solution pH 
ultimately having a negative impact on the continuation 
of chemotherapy (Kuwahara et  al. 1998; Yoshida et  al. 
2012).
Pain is complicated human experience, and tissue dam-
age is not the only determinant of the extent of pain, 
which is a subjective, personal, and multidimensional 
experience, and not merely a simple sensation (Turk and 
Melzack 1992). Pain processes do not begin with the stim-
ulation of receptors. Rather, injury or disease produces 
neural signals that enter an active nervous system that 
is the substrate of past experience, culture, and a host of 
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other environmental and personal factors (Melzack and 
Katz 2013). Pain is presently estimated using subjective 
methods, such as the visual analog scale (VAS) (McCor-
mack et al. 1988; DeLoach et al. 1998; Fishbain et al. 2016). 
VAS is a subjective self-assessment method for grading 
pain relative to the most intense pain that the patient has 
ever experienced (Babul et  al. 1993; Huguet et  al. 2010). 
Because of the usability, VAS has become a common tool 
for the quantification of pain intensity and pain relief. This 
method has proven to be a valid and reliable means to 
assess depression, pain, mood, and anxiety (McCormack 
et al. 1988; Lener et al. 2016). VAS consists of a line having 
a predetermined length and direction, with bilateral lim-
its that indicate absence or minimum amount of the cited 
phenomenon on one end, and maximum or full amount 
of the phenomenon on the other. Verbal rating scale 
(VRS), has a variable number of gradually ascending ver-
bal descriptors; the other approach, called a numeric rat-
ing score (NRS), also has a variable number of categories, 
most commonly 5 or 10 (Lara-Munoz et  al. 2004). NRS 
and VRS are insufficient to evaluate VP because the meth-
ods cannot differentiate small changes in pain (Hjermstad 
et  al. 2011; Mujezinovic and Alfirevic 2011). NRS and 
VRS thus allow only a less-subtle distinction of pain lev-
els compared with PainVision™ PS-2100 system (PV; 
Nipro Co., Osaka, Japan)/VAS, where there are a theo-
retically unlimited number of possible answers. Therefore, 
we chose VAS to assess VP. However, researchers have 
reported that 7–20% of patients are unable to complete 
VAS (Kremer et al. 1981; Revill et al. 1976; Gregory 2012). 
Evaluation of pain can vary depending on the physical 
state and mood of the patient at the time of evaluation; 
thus, it is desirable to objectively evaluate pain. Pain eval-
uation by VAS is related with a margin of error of about 
±20  mm (DeLoach et  al. 1998). Therefore, a method to 
objectively assess pain is also required when evaluating 
drugs designed to improve VP.
The PV was developed in clinical practice for quantita-
tive analysis of pain perception (Matsumura et  al. 2012; 
Lee et al. 2014; Ohtori et al. 2014; Hiraki et al. 2014; Kim 
et al. 2014; Fukada et al. 2011; Yoshida et al. 2015c). PV is 
an analytical device that was designed to objectively and 
quantitatively assess patient sense nociception and per-
ception. The PV apparatus can stimulate Aβ and Aδ fibers, 
and the degree of pain is calculated from two variables, 
the current perception threshold and current produc-
ing comparable pain as measured by this instrument. Its 
advantages include the ability to evaluate pain relatively 
rapidly and without causing additional pain to the patient. 
Although we reported that VAS and PV are useful to eval-
uate oxaliplatin-induced peripheral neuropathy with the 
aim of aiding treatment (Yoshida et al. 2015c), there have 
been no reports concerning the use of these measures for 
the assessment of VP due to oxaliplatin. Therefore, the 
purpose of this study was to identify potential correlations 
between the results of subjective and objective assessment 
methods to evaluate oxaliplatin-induced VP as measured 
using PV and VAS, respectively.
Methods
Patients
The institutional review board at Fukuoka University 
approved the protocol (Approval no: 13-4-07).
Patients with histologically confirmed metastatic CRC 
who had not received chemotherapy or who had com-
pleted adjuvant chemotherapy during the last 6 months 
were enrolled in this study. Patients with a poor mental 
health that prevented understanding of the concepts of 
PV and VAS were excluded. Patients were also excluded 
if they had experienced any musculoskeletal pain or 
peripheral sensory neuropathy prior to chemotherapy 
that may have disrupted the quantitative measurement 
of pain. Written informed consent was obtained from all 
patients.
Chemotherapy
A total of 58 patients with metastatic CRC who under-
went XELOX plus bevacizumab therapy (7.5  mg/kg 
bevacizumab and 130  mg/m2 oxaliplatin on day 1 plus 
2000  mg/m2 capecitabine on days 1–14, repeated every 
3  weeks) or XELOX therapy (130  mg/m2 oxaliplatin 
on day 1 plus 2000  mg/m2 capecitabine on days 1–14, 
repeated every 3  weeks) (Yoshida et  al. 2015a, b) at 
Fukuoka University Hospital between April and August 
2014 were included in this study.
Data collection
VAS is a commonly used method to evaluate variations 
in pain intensity. Subjects were instructed to indicate the 
strength of pain at the time of assessment by marking on 
a 100 mm horizontal line anchored with “0 (no pain)” on 
the left edge and “100 (worst pain imaginable)” on the 
right edge (Yoshida et al. 2015c).
For PV measurement, an electrode was attached to the 
medial side of the upper arm (Fig. 1) and an electric current 
of increasing amplitude is applied (50 Hz; 0–150 µA rms; 
pulse width: 0.3  ms). The patient was ordered to push a 
switch when this stimulation was perceived for the first 
time. The current at the point was defined as the “mini-
mum perceived current” value. As the stimulation current 
was increased, the patient was ordered to push the button 
when the intensity of the stimulation current was equiva-
lent to that of VP. The current at this point was defined 
as the “pain equivalent current” value. Using the values 
obtained, “pain intensity” was calculated using the afore-
mentioned formula. When there was not a pain, the value 
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was 0. The intensity and score then increased according to 
the degree of pain, with no upper limit. Each measurement 
was easy and can be performed within 2 min. The two pain 
assessments with VAS and PV were performed at the same 
time on the same set of patients (paired sampling), and the 
assessments were repeated within the same time interval 
(repeated measurements). VP assessment was performed 
by same nurse who received training.
Data analysis
Data were analyzed using SAS software ver. 9.3 (SAS 
Institute, Cary, NC, USA). To evaluate the reliability of 
the device in terms of internal consistency, we assessed 
the quantitative pain degree score twice. Data are 
reported as the mean  ±  standard deviation, median 
(25–75% interquartile range), or number (percentage) of 
participants. Partial correlation analysis was carried out 
to estimate the relationship between VAS and PV after 
adjusting for subject and sex. In other words, the cor-
relation coefficient between VAS and PV was calculated 
using residual values of the mixed-effects model includ-
ing sex as a fixed effect and subject as a random effect. A 
probability (p) value of <0.05 was considered statistically 
significant.
Results
A total of 64 patients received chemotherapy for meta-
static CRC between April and August 2014. Six patients 
were excluded from the analysis according to the inclusion 
criteria (5 patients with ECOG PS 2 and one because of 
inadequate hematological, liver, and renal function). The 
final cohort included 18 women and 40 men (median age, 
65  years; range 43–80  years). The characteristics of the 
study patients are shown in Table 1. Among the patients 
evaluated, 81.0% had ECOG PS 0, with the liver being the 
most common site of metastasis. The cumulative median 
dose of oxaliplatin was 1751 mg/body (range: 345–5903), 
and the number of cycles was 10. Grade 3–4 hematologi-
cal toxicity and grade 3–4 non-hematological toxicity were 
recorded for 12.1 and 17.2% of patients, respectively.
VP was assessed using both PV and VAS a total of 173 
chemotherapy cycles. The mean VAS and PV scores for 
VP were 24.8 (range: 0–100) and 44.5 (range: 0–596), 
respectively. The partial correlation coefficients with no 
adjustment, after adjusting for subject and sex, and after 
exclusion of outliers (one patient) were 0.49 (p < 0.0001), 
0.41 (p  <  0.0001), and 0.45 (p  <  0.0001), respectively 
(Table 2). A corresponding scatter plot and 95% predic-
tion ellipse are shown in Fig. 2.
Discussion
The correlation between VAS and PV to evaluate vascu-
lar pain related to oxaliplatin infusion is weak. However, 
it may be a matter of course. The pain is characterized by 
various dimensions including physical, social, and psy-
chological; which together constitute the total pain. Total 
pain is not simply the end product of a linear sensory 
transmission system. VAS expresses the total pain, and 
PV expresses a physical pain. Therefore, it may be natu-
ral that there is no strong correlation between VAS and 
PV. It is thought that we should evaluate the physical pain 
using PV to improve the vascular pain.
Fig. 1 PV method of pain evaluation. Bipolar electrodes are attached 
to patients on the ulnar side of the forearm. Patients grasp a switch 
using their contralateral hand
Table 1 Baseline characteristics of  patients who received 
chemotherapy
N (%) Mean SD Range















Adverse events (Grade 3–4)
Hematological 7 (12.1)
Non-hematological 10 (17.2)
Oxaliplatin (mg/body) 1751 136.6 345–5903
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We previously reported port-free chemotherapy 
administration via the median cubital vein for CRC and 
showed that the resulting low complication rates helped 
to ensure completion of chemotherapy without delay for 
most patients (Yoshida et al. 2012, b). However, VP occa-
sionally necessitates changing an oxaliplatin drip infu-
sion to a peripheral vein during XELOX therapy. Some 
investigators have reported that the addition of dexa-
methasone (DEX) to an oxaliplatin drip infusion can help 
control vascular pain (Matsuyama et al. 2011). We evalu-
ated the effectiveness of DEX for controlling VP caused 
by oxaliplatin administration via a peripheral vein dur-
ing XELOX therapy (Yoshida et  al. 2012). However, VP 
did not completely disappeared. Therefore, we aimed to 
establish a new evaluation method of VP.
VAS tends to focus only on pain intensity, with an 
increased risk for over-simplification of the experience 
(Bonica et  al. 1990). Furthermore, actual assessments 
are relative only to the individual being assessed. Same 
stimulation applied to different individuals can give 
remarkably different scores. Pain is a subjective, per-
sonal, and multidimensional experience rather than just 
a simple sensation (Turk and Melzack 1992; Burton et al. 
2014). Therefore, pain evaluation is complicated process, 
and it is imperative that it takes into account the many 
factors that affect the experience of pain. The disadvan-
tages of VAS are that patients oversimplify the pain expe-
rience, and some patients find it difficult to express their 
individual, subjective, multidimensional experience of 
pain as a mark on a line.
There is no simple tool to objectively record the degree 
and type of pain experienced by a patient. To help address 
this need, the newly developed PV device was recently 
introduced for quantitative assessment of pain sensa-
tion and perception through direct measurement of pain 
intensity as a “degree of pain.” In clinical practice, this 
device has been used to evaluate not only chronic pain, 
such as lower back pain caused by spondylolisthesis (Lee 
et al. 2014) or fibromyalgia (Osada et al. 2011), but also to 
assess acute pain due to the removal of wound dressing 
materials (Matsumura et  al. 2012). They have reported 
that PV is a useful device to objectively evaluate pain in 
various fields. The system is based on the supply of alter-
native painless sensory stimulation equivalent to pain 
(through the stimulation of Aβ and Aδ sensory nerve fib-
ers) and the measurement of the degree of the stimula-
tion. Because individual pain thresholds are assessed first 
for accurate subsequent measurement with the method, 
Table 2 Partial correlation coefficient analysis 
between VAS and PV
a Partial correlation coefficient adjusted by subject and sex
b Partial correlation coefficient excluding outlier, PV = 596 (sensitivity analysis)
Correlation coefficient P value
No adjustment 0.490 <0.0001
Partiala 0.408 <0.0001
Exclusion of outlierb 0.450 <0.0001
Fig. 2 Correlation coefficient between VAS and PV scores adjusted for subject and sex
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pain intensity can be quantitatively compared among 
patients. Therefore, this method enables a more objec-
tive assessment in comparison with other generally used 
methods. However, there are currently no published 
reports on the use of PV to evaluate VP. Prevention and 
improvement of oxaliplatin-induced VP is critical to 
improve patients’ quality of life and support continuation 
of treatment.
A method to compare two intra-individual coefficients 
of variations (CVs) considering the paired sampling, dif-
ferent inter-individual variations between measures 
and some covariates have been proposed (Kiyomi et  al. 
2016). Two measurements by PV and VAS are performed 
simultaneously. To evaluate within patient consistency, 
intra-individual CVs are compared between measures 
assuming that the pain status of each patient is stable 
during the study period. The correlated samples and dif-
ferent inter-individual variations due to different scales of 
the measures should be taken into account in the statisti-
cal analysis. This adjustment of covariates improves the 
estimation of population mean values of the measures. 
The approach is useful to compare two intra-individual 
CVs taking into account the paired sampling and differ-
ent inter-individual variations between measures and 
some covariates.
To the best of our knowledge, there is no report that 
has quantified oxaliplatin-induced VP using electrical 
stimulation. One limitation of this study was using only 
VAS as a subjective evaluation and not allowing adequate 
VP assessment. Accordingly, the Neuropathic Pain Ques-
tionnaire, Leeds Assessment of Neuropathic Symptoms, 
and Signs scale and Douleur Neuropathique en 4 Ques-
tions should also be compared to confirm the current 
findings. We think that the drug effects for oxaliplatin-
induced VP should be evaluated objectively.
Conclusions
Although both assessment methods evaluated the same 
phenomenon, a strong correlation was not observed 
between the results of each assessment method, and 
only a weak correlation was observed between PV and 
VAS. These results suggest that because PV and VAS 
each measure different factors, both may be needed to 
adequately evaluate oxaliplatin-induced VP with the 
aim of aiding treatment. These findings are expected 
to help with the improvement of VP through the 
usage of an objective assessment method and to sup-
port future clinical trials associated with VP caused by 
oxaliplatin.
Authors’ contributions
YoYo designed and drafted the manuscript. AM, NA, TY, TaMa, DK and ToMe 
collected data. ToKo evaluated pain intensity. FK performed statistical analysis. 
KN, YT, KT, YuYa and SH helped with data analyses. All authors read and 
approved the final manuscript.
Author details
1 Department of Gastroenterological Surgery, Fukuoka University Faculty 
of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. 2 Division 
of Oncology, Hematology and Infectious Diseases, Department of Internal 
Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan. 3 Academia, 
Industry and Government Collaborative Research Institute of Translational 
Medicine for Life Innovation, Fukuoka University, Fukuoka, Japan. 4 Clinical 
Research Assist Center, Fukuoka University Hospital, Fukuoka, Japan. 
Acknowledgements
We gratefully acknowledge the participating patients, their family members, 
and all researchers involved in this study. We thank Aya Tanaka for collecting 
data. This study was presented at the 2015 Gastrointestinal Cancers Sympo-
sium, and this paper is the first to publish the overall results as an original 
article.
Competing interests
The authors declare that they have no competing interests.
Received: 19 April 2016   Accepted: 19 October 2016
References
Babul N, Darke AC, Johnson DH, Charron-Vincent K (1993) Using memory for 
pain in analgesic research. Ann Pharmacother 27(1):9–12
Bonica JJ, Loeser JD, Chapman CR, Fordyce WE, Domenowske M (1990) The 
management of pain, vol 1. Philadelphia, Lea & Febiger
Burton AW, Chai T, Smith LS (2014) Cancer pain assessment. Curr Opin Support 
Palliat Care 8(2):112–116. doi:10.1097/spc.0000000000000047
DeLoach LJ, Higgins MS, Caplan AB, Stiff JL (1998) The visual analog scale in 
the immediate postoperative period: intrasubject variability and correla-
tion with a numeric scale. Anesth Analg 86(1):102–106
Fishbain DA, Gao J, Lewis JE, Zhang L (2016) At completion of a multidiscipli-
nary treatment program, are psychophysical variables associated with 
a VAS improvement of 30% or more, a minimal clinically important dif-
ference, or an absolute VAS score improvement of 1.5 cm or more? Pain 
Med 17(4):781–789. doi:10.1093/pm/pnv006
Fukada T, Iwakiri H, Ozaki M (2011) A randomised double-blind crossover 
trial of the potential analgesic effect of a transdermal nicotine patch 
in non-smokers based on objective and subjective assessment. Eur J 
Anaesthesiol 28(8):592–596. doi:10.1097/EJA.0b013e328347dfd4
Gregory J (2012) How can we assess pain in people who have difficulty com-
municating? A practice development project identifying a pain assess-
ment tool for acute care. Int Pract Develop J 2(2):6–20
Hiraki M, Takemasa I, Uemura M, Haraguchi N, Nishimura J, Hata T, Mizushima 
T, Yamamoto H, Doki Y, Mori M (2014) Evaluation of invasiveness in single-
site laparoscopic colectomy, using “the PainVision system” for quantitative 
analysis of pain sensation. Surg Endosc 28(11):3216–3223. doi:10.1007/
s00464-014-3594-7
Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, 
Fainsinger R, Aass N, Kaasa S (2011) Studies comparing Numerical Rating 
Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment 
of pain intensity in adults: a systematic literature review. J Pain Symptom 
Manag 41(6):1073–1093. doi:10.1016/j.jpainsymman.2010.08.016
Huguet A, Stinson JN, McGrath PJ (2010) Measurement of self-reported pain 
intensity in children and adolescents. J Psychosom Res 68(4):329–336. 
doi:10.1016/j.jpsychores.2009.06.003
Kim J, Lee KS, Kong SW, Kim T, Kim MJ, Park SB, Lee KH (2014) Correlations 
between electrically quantified pain degree, subjectively assessed visual 
analogue scale, and the McGill pain questionnaire: a pilot study. Ann 
Rehabil Med 38(5):665–672. doi:10.5535/arm.2014.38.5.665
Kiyomi F, Nishikawa M, Yoshida Y, Noda K (2016) Comparison of intra-individual 
coefficients of variation on the paired sampling data when inter-individ-
ual variations are different between measures. BMC Res Notes 9(1):115. 
doi:10.1186/s13104-016-1912-y
Page 6 of 6Yoshida et al. SpringerPlus  (2016) 5:1872 
Kremer EF, Block A, Gaylor MS (1981) Behavioral approaches to treatment of 
chronic pain: the inaccuracy of patient self-report measures. Arch Phys 
Med Rehabil 62(4):188–191
Kuwahara T, Asanami S, Kubo S (1998) Experimental infusion phlebitis: 
tolerance osmolality of peripheral venous endothelial cells. Nutrition 
14(6):496–501
Lara-Munoz C, De Leon SP, Feinstein AR, Puente A, Wells CK (2004) Comparison 
of three rating scales for measuring subjective phenomena in clinical 
research. I. Use of experimentally controlled auditory stimuli. Arch Med 
Res 35(1):43–48. doi:10.1016/j.arcmed.2003.07.007
Lee HJ, Seo JC, Kwak MA, Park SH, Min BM, Cho MS, Shin I, Jung JY, Roh 
WS (2014) Acupuncture for low back pain due to spondylolisthesis: 
study protocol for a randomized controlled pilot trial. Trials 15:105. 
doi:10.1186/1745-6215-15-105
Lener MS, Kundu P, Wong E, Dewilde KE, Tang CY, Balchandani P, Murrough JW 
(2016) Cortical abnormalities and association with symptom dimen-
sions across the depressive spectrum. J Affect Disord 190:529–536. 
doi:10.1016/j.jad.2015.10.027
Matsumura H, Imai R, Gondo M, Watanabe K (2012) Evaluation of pain 
intensity measurement during the removal of wound dressing material 
using ‘the PainVision system’ for quantitative analysis of perception 
and pain sensation in healthy subjects. Int Wound J 9(4):451–455. 
doi:10.1111/j.1742-481X.2011.00911.x
Matsuyama K, Mishima H, Ueno H, Kajihara K, Morioka A, Morimoto S, 
Yamauchi K, Honda Y, Komori K, Tsujinaka T (2011) Etiology and manage-
ment of venous pain during intravenous administration of oxaliplatin. 
Gan To Kagaku Ryoho 38(3):411–414
McCormack HM, Horne DJ, Sheather S (1988) Clinical applications of visual 
analogue scales: a critical review. Psychol Med 18(4):1007–1019
Melzack R, Katz J (2013) Pain. Wiley interdisciplinary reviews. Cognit Sci 
4(1):1–15. doi:10.1002/wcs.1201
Mujezinovic F, Alfirevic Z (2011) Analgesia for amniocentesis or chorionic villus 
sampling. The Cochrane Library
Ohtori S, Kawaguchi H, Takebayashi T, Orita S, Inoue G, Yamauchi K, Aoki 
Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, 
Sakuma Y, Oikawa Y, Inage K, Sainoh T, Sato J, Takahashi K, Konno S (2014) 
PainVision apparatus is effective for assessing low back pain. Asian Spine 
J 8(6):793–798. doi:10.4184/asj.2014.8.6.793
Osada K, Oka H, Isomura T, Nakamura I, Tominaga K, Takahashi S, Kojima 
A, Nishioka K (2011) Development of the Japanese version of the 
Fibromyalgia Impact Questionnaire (JFIQ): psychometric assess-
ments of reliability and validity. Int J Rheum Dis 14(1):74–80. 
doi:10.1111/j.1756-185X.2010.01585.x
Revill SI, Robinson JO, Rosen M, Hogg MI (1976) The reliability of a linear ana-
logue for evaluating pain. Anaesthesia 31(9):1191–1198
Turk D, Melzack R (1992) Trends and future directions in human pain assess-
ment. Handbook of pain assessment. p 473–479
Yoshida Y, Hoshino S, Aisu N, Shiwaku H, Beppu R, Tanimura S, Yamashita Y 
(2012) Dexamethasone as a means not only for controlling vascular pain 
caused by the administration of oxaliplatin via the peripheral vein but 
also for controlling oxaliplatin-induced hypersensitivity reactions. Br J 
Med Med Res 2(2):132–141
Yoshida Y, Hoshino S, Aisu N, Mogi A, Yamada T, Kojima D, Tanimura S, Hirata 
K, Yamashita Y (2015a) Can grade 2 neutropenia predict the risk of 
grade 3 neutropenia in metastatic colorectal cancer patients treated 
with chemotherapy? Supp Care Cancer 23(6):1623–1627. doi:10.1007/
s00520-014-2518-3
Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Mogi A, Tanaka T, Hirata K, 
Tamura K, Yamashita Y (2015b) Administration of chemotherapy via the 
median cubital vein without implantable central venous access ports: 
port-free chemotherapy for metastatic colorectal cancer patients. Int J 
Clin Oncol 20(2):332–337. doi:10.1007/s10147-014-0703-5
Yoshida Y, Mogi A, Yamada T, Aisu N, Matsuoka T, Kojima D, Tanimura 
S, Koganemaru T, Oda M, Fukuda M, Kiyomi F, Noda K, Hirata K, 
Yamashita Y (2015c) Subjective and objective assessment of oxaliplatin-
induced peripheral neuropathy. SpringerPlus 4:822. doi:10.1186/
s40064-015-1646-7
